Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Naoe

Showing results (211-220 of 288) with videos related to

Pageof 29
Sort By:
Cancer Science|November 12, 2013
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsTakaaki Ono, Akihiro Takeshita, Yuji Kishimoto, et al.
Journal of Human Genetics|November 14, 2009
Mutation of ARHGAP9 in patients with coronary spastic anginaMikito Takefuji, Hiroyuki Asano, Kazutaka Mori, et al.
Leukemia Research|January 18, 2011
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assayTakaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, et al.
Cancer Science|July 28, 2012
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemiaTakaaki Ono, Akihiro Takeshita, Yuji Kishimoto, et al.
Blood|November 8, 2003
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemiaKazutaka Ozeki, Hitoshi Kiyoi, Yuka Hirose, et al.
Cancer Science|May 29, 2012
Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancyYachiyo Kuwatsuka, Akio Kohno, Seitaro Terakura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|May 29, 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 StudyAtsushi Wakita, Shigeki Ohtake, Satoru Takada, et al.
Leukemia Research|July 2, 2013
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Pageof 29

Showing results (211-220 of 288) with videos related to

Sort By:
Pageof 29
Cancer Science|November 12, 2013
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsTakaaki Ono, Akihiro Takeshita, Yuji Kishimoto, et al.
Journal of Human Genetics|November 14, 2009
Mutation of ARHGAP9 in patients with coronary spastic anginaMikito Takefuji, Hiroyuki Asano, Kazutaka Mori, et al.
Leukemia Research|January 18, 2011
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assayTakaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, et al.
Cancer Science|July 28, 2012
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemiaTakaaki Ono, Akihiro Takeshita, Yuji Kishimoto, et al.
Blood|November 8, 2003
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemiaKazutaka Ozeki, Hitoshi Kiyoi, Yuka Hirose, et al.
Cancer Science|May 29, 2012
Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancyYachiyo Kuwatsuka, Akio Kohno, Seitaro Terakura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study GroupMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
International Journal of Hematology|May 29, 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 StudyAtsushi Wakita, Shigeki Ohtake, Satoru Takada, et al.
Leukemia Research|July 2, 2013
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)Noriyoshi Iriyama, Yoshihiro Hatta, Jin Takeuchi, et al.
Haematologica|January 29, 2008
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapyMasamitsu Yanada, Jin Takeuchi, Isamu Sugiura, et al.
Pageof 29